IRON — Disc Medicine, Inc. Stock Price, Chart & AI Report

Negative Jul 15, 2026 • 21:50 UTC GlobeNewswire Inc. • Rosen Law Firm

Putnam Investor News: If You Have Suffered Losses in Putnam Investment Management LLC, You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against Putnam Investment Management LLC, Sportradar Group AG, and Disc Medicine Inc., alleging materially misleading business information was issued to investors. Affected investors are encouraged to join class action lawsuits seeking compensation for losses.

SRAD IRON securities fraud class action lawsuit investor losses misleading information mutual funds shareholder rights

Sentiment note

Company is under investigation for potential securities claims by Rosen Law Firm on behalf of shareholders, suggesting alleged misconduct or misleading disclosures.

Negative Jul 15, 2026 • 19:04 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, rejecting the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused Disc Medicine's stock to fall 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

IRON securities class action FDA rejection Complete Response Letter bitopertin stock decline investor losses drug approval

Sentiment note

The company received an FDA Complete Response Letter rejecting its new drug application for bitopertin, indicating the drug cannot be approved without additional evidence. This regulatory setback resulted in a 22% stock price decline and triggered securities litigation, representing a significant negative development for the company and its investors.

Negative Jul 11, 2026 • 19:01 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, citing uncertainties requiring additional evidence. The stock fell 22% following the announcement. Investors who suffered losses are encouraged to join a prospective class action.

IRON securities class action FDA Complete Response Letter bitopertin program stock price decline investor losses new drug application

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, indicating regulatory setback and uncertainty. Stock price fell 22% on the news, and the company is now subject to securities litigation investigation for allegedly issuing materially misleading business information.

Negative Jul 9, 2026 • 00:01 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) for allegedly issuing materially misleading business information. The investigation was triggered by an FDA Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, which caused the stock to fall 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

IRON securities class action FDA Complete Response Letter bitopertin program investor losses stock decline misleading business information

Sentiment note

The company received an FDA Complete Response Letter denying approval of its new drug application for bitopertin, indicating regulatory setback and uncertainty. The stock fell 22% on the news, and the company is now subject to securities litigation investigation for allegedly issuing materially misleading information to investors.

Negative Jul 6, 2026 • 01:58 UTC GlobeNewswire Inc. • The Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Disc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused the stock to plummet 22%. The Rosen Law Firm is now pursuing a class action lawsuit on behalf of shareholders who suffered losses, alleging the company issued materially misleading business information.

IRON FDA rejection Complete Response Letter securities class action stock price decline bitopertin program investor losses drug approval

Sentiment note

The company received an FDA rejection for its lead drug candidate (bitopertin), resulting in a 22% stock price decline on the announcement date. The rejection indicates significant setbacks in the company's pipeline and has triggered securities litigation alleging misleading disclosures to investors.

Negative Jul 2, 2026 • 01:27 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. The stock price fell 22% on the news, and investors who suffered losses are encouraged to join a prospective class action lawsuit.

IRON securities class action FDA Complete Response Letter bitopertin program new drug application investor losses stock price decline

Sentiment note

FDA issued a Complete Response Letter denying approval of the bitopertin NDA due to uncertainties requiring additional evidence, resulting in a 22% stock price decline and triggering securities litigation investigation for allegedly issuing materially misleading business information.

Negative Jun 29, 2026 • 00:38 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EMBC

Rosen Law Firm has filed class action lawsuits against Embecta Corp. for allegedly making false statements about fiscal results and pen needle business performance, cutting 2026 guidance. The firm is also investigating claims against Zoetis Inc. and Disc Medicine Inc. Investors who purchased securities during specified periods may be eligible for compensation.

EMBC ZTS IRON class action lawsuit securities fraud misleading statements investor compensation lead plaintiff deadline

Sentiment note

Company is under investigation by Rosen Law Firm for potential securities claims on behalf of shareholders, suggesting alleged violations or misrepresentations.

Negative Jun 28, 2026 • 21:41 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) for allegedly issuing materially misleading business information. The investigation was triggered by an FDA Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, which caused the stock to fall 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

IRON securities class action FDA Complete Response Letter bitopertin program stock price decline investor losses misleading business information

Sentiment note

The company received an FDA Complete Response Letter denying approval of its bitopertin NDA, indicating regulatory setback and uncertainty. The stock fell 22% on the news, and the company is now subject to a securities class action investigation for allegedly issuing materially misleading information to investors.

Negative Jun 21, 2026 • 17:09 UTC GlobeNewswire Inc. • The Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, that rejected the company's bitopertin drug application due to insufficient evidence. The rejection caused Disc Medicine's stock to plummet 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

IRON FDA rejection Complete Response Letter bitopertin securities class action stock price decline investor losses drug approval

Sentiment note

The company received an FDA Complete Response Letter rejecting its new drug application for bitopertin, indicating the drug cannot be approved without additional evidence. This regulatory setback triggered a 22% stock price decline and prompted a securities class action investigation for allegedly issuing materially misleading business information.

Negative Jun 19, 2026 • 03:41 UTC GlobeNewswire Inc. • The Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. The firm is preparing a class action lawsuit to recover investor losses.

IRON securities class action FDA Complete Response Letter bitopertin program new drug application investor losses stock price decline

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, citing uncertainties requiring additional evidence. This regulatory setback resulted in a 22% stock price decline and triggered a securities class action investigation for allegedly issuing materially misleading business information.

Negative Jun 15, 2026 • 23:25 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine (IRON), TruBridge (TBRG), and PennyMac Financial Services (PFSI) for allegedly issuing materially misleading business information. Disc Medicine's stock fell 22% on February 13, 2026, following an FDA Complete Response Letter rejecting its bitopertin program NDA. Investors who suffered losses are encouraged to join prospective class action lawsuits.

IRON TBRG PFSI securities fraud class action lawsuit FDA rejection investor losses Complete Response Letter

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, resulting in a 22% stock price decline and triggering securities fraud investigation for allegedly misleading investors.

Negative Jun 12, 2026 • 19:54 UTC GlobeNewswire Inc. • Rosen Law Firm

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against multiple companies. Disc Medicine (IRON) received an FDA Complete Response Letter on its bitopertin program, causing a 22% stock price decline on February 13, 2026. The firm is also pursuing class action lawsuits against DNOW Inc. and Badger Meter, Inc. on behalf of affected shareholders.

IRON DNOW BMI securities class action FDA Complete Response Letter investor losses stock price decline shareholder litigation

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, indicating regulatory setback and uncertainty. Stock fell 22% on the news, and the company is subject to securities litigation investigation for allegedly issuing materially misleading information.